Clinical Trials

6 enrolled

Head and Neck Neoplasms, Recurrence

NCT06525220 2026-03-27

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

500 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT04858269 2026-03-24

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Phase 2 Recruiting

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT06788990 2026-03-23

FORTIFI-HN01

Phase 2/3 Recruiting

650 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT07484139 2026-03-20

NEO COMBAT XL

26 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

DermatologicGenitourinaryGynecologicHead & NeckThoracic

35 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Phase 1/2 Recruiting

300 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

GastrointestinalHead & Neck

7 enrolled 14 charts

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05787587 2026-02-09

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

216 enrolled

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related, Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03040999 2026-02-04

KEYNOTE-412

Phase 3 Completed

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

78 enrolled

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT04266730 2026-01-28

PANDA-VAC

6 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

NCT03978689 2026-01-22

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

80 enrolled

Head and Neck Neoplasms

NCT06736379 2026-01-20

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

41 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms

NCT02296684 2026-01-15

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

67 enrolled 15 charts

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

126 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT06998069 2025-12-30

Head and Neck Cancer Study Project in the Geriatric Population

Phase 3 Recruiting

20 enrolled

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

296 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Phase 1/2 Recruiting

242 enrolled

GastrointestinalHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Completed

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

36 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

NCT02586207 2025-10-07

Pembrolizumab in Combination With CRT for LA-SCCHN

59 enrolled 9 charts

Phase 2 Active not recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Diseases, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03383094 2025-10-07

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT02841748 2025-10-01

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Phase 2 Active not recruiting

100 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04260126 2025-10-01

VERSATILE002

95 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

42 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04180215 2025-09-15

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Phase 1/2 Completed

198 enrolled

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Neoplasms, Squamous Cell

NCT05252429 2025-09-12

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

27 enrolled

Phase 3 Active not recruiting

Head and Neck Neoplasms

NCT03765918 2025-08-20

MK-3475-689

714 enrolled 90 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04429542 2025-08-15

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

GastrointestinalGynecologicHead & Neck

292 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

DermatologicGenitourinaryHead & NeckThoracic

146 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors